

**ASX RELEASE**

**Volpara Quarterly Results and Investor Conference Call**

Wellington, NZ, 23 January 2018: [Volpara Health Technologies](#) ("Volpara"; ASX: VHT), a digital health company focused on early detection of breast cancer by improving quality of screening using artificial intelligence (AI), is pleased to advise it will release its Appendix 4C – Quarterly Cash Flow Statement for the period ended 31 December 2017 (Q2 FY18) on 24 January 2018.

Investors are invited to join a conference call hosted by CEO, Dr Ralph Highnam, CFO Craig Hadfield and CCO Mark Koeniguer at 9am AEDT (11am NZDT) Wednesday 24 January 2018.

To pre-register please follow this link:

<https://services.choruscall.com.au/diamondpass/volpara-590281-invite.html>

*You will receive a calendar notification with dial-in details and PIN for fast-track access to the call.*

ENDS.

**About Volpara Health Technologies Limited (ASX: VHT)**

Founded in 2009 from research originally conducted at Oxford University, VHT is based in Wellington, New Zealand and facilitates the early detection of breast cancer through its digital health solutions to enable personalised, high-quality breast cancer screening based on objective measurements of breast density.

VHT has a number of patents and trademarks and regulatory clearances, including FDA and CE, supporting its technology and services. An ASX-listed company that raised A\$20M through an IPO and subsequent share placement and rights issue in 2016, VHT has customers and/or research projects in 36 countries.

[www.volparasolutions.com](http://www.volparasolutions.com)

**For further information, please contact:**

Ralph Highnam, CEO  
Volpara Health Technologies  
[ralph.highnam@volparasolutions.com](mailto:ralph.highnam@volparasolutions.com)  
t: +64 21 149 0541

Kyahn Williamson  
WE Buchan  
[kwilliamson@buchanwe.com.au](mailto:kwilliamson@buchanwe.com.au)  
t: +61 3 9866 4722